Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3351139
Max Phase: Preclinical
Molecular Formula: C10H19NO6
Molecular Weight: 249.26
Molecule Type: Small molecule
Associated Items:
ID: ALA3351139
Max Phase: Preclinical
Molecular Formula: C10H19NO6
Molecular Weight: 249.26
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CCCC(=O)N[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O
Standard InChI: InChI=1S/C10H19NO6/c1-2-3-6(13)11-10-9(16)8(15)7(14)5(4-12)17-10/h5,7-10,12,14-16H,2-4H2,1H3,(H,11,13)/t5-,7-,8+,9-,10+/m1/s1
Standard InChI Key: XOHMAPSXUCVOKP-HOQQJHGQSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 249.26 | Molecular Weight (Monoisotopic): 249.1212 | AlogP: -2.30 | #Rotatable Bonds: 4 |
Polar Surface Area: 119.25 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 5 |
#RO5 Violations: 0 | HBA (Lipinski): 7 | HBD (Lipinski): 5 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 11.62 | CX Basic pKa: | CX LogP: -2.08 | CX LogD: -2.08 |
Aromatic Rings: 0 | Heavy Atoms: 17 | QED Weighted: 0.38 | Np Likeness Score: 1.01 |
1. Pastor M, Cruciani G, Clementi S.. (1997) Smart region definition: a new way to improve the predictive ability and interpretability of three-dimensional quantitative structure-activity relationships., 40 (10): [PMID:9154968] [10.1021/jm9608016] |
2. Venkatarangan P, Hopfinger AJ.. (1999) Prediction of ligand-receptor binding thermodynamics by free energy force field three-dimensional quantitative structure-activity relationship analysis: applications to a set of glucose analogue inhibitors of glycogen phosphorylase., 42 (12): [PMID:10377222] [10.1021/jm980515p] |
3. Pan D, Liu J, Senese C, Hopfinger AJ, Tseng Y.. (2004) Characterization of a ligand-receptor binding event using receptor-dependent four-dimensional quantitative structure-activity relationship analysis., 47 (12): [PMID:15163189] [10.1021/jm030586a] |
4. Zamora I, Oprea T, Cruciani G, Pastor M, Ungell AL.. (2003) Surface descriptors for protein-ligand affinity prediction., 46 (1): [PMID:12502357] [10.1021/jm011051p] |
5. Pastor M, Cruciani G, Watson KA.. (1997) A strategy for the incorporation of water molecules present in a ligand binding site into a three-dimensional quantitative structure--activity relationship analysis., 40 (25): [PMID:9406599] [10.1021/jm970273d] |
6. Gohlke H, Klebe G.. (2002) DrugScore meets CoMFA: adaptation of fields for molecular comparison (AFMoC) or how to tailor knowledge-based pair-potentials to a particular protein., 45 (19): [PMID:12213058] [10.1021/jm020808p] |
7. So SS, Karplus M.. (1997) Three-dimensional quantitative structure-activity relationships from molecular similarity matrices and genetic neural networks. 2. Applications., 40 (26): [PMID:9435905] [10.1021/jm970488n] |
8. Uddin R, Saeed M, Ul-Haq Z. (2013) Molecular docking- and genetic algorithm-based approaches to produce robust 3D-QSAR models, [10.1007/s00044-013-0812-0] |
Source(1):